Replies to post #326540 on Amarin Corp Plc (AMRN)

[ggwpq]

ralphey, I thought Amarin has a stronger case Vs Hikma than GSK Vs Teva. Amarin's CVD indications >> SHTG indications while GSK CHF indications < Teva's other indications. Amarin might not be able to survive with Hikma's allerged induced infringement while GSK has no such issue with Teva's allerged induced infringement. So I don't see your point.

[dukesking]

Ralphy, Benecard shows blatant disregard for the protected carve out indication. They state right under their name that they are a “carve out prescription drug program” so they no better. IMO. I’ve made Amarin IR aware of these details. Additionally, I love your idea of a citizen petition to the FDA regarding Lovaza, generic lovaza, and all mixed omega 3 ethyl esters. I believe it would be powerful coming from a group of informed and concerned doctors such as yourself, HK, Gbert, jomama, and others on this board. I hope you all will seriously consider collaborating and submitting one. TIA.

[Birdbrain Ideas]

If Amarin's lawsuit against Hikma has scared off other generics and slowed Hikma's rollout, Amarin's already scored a major legal victory. You don't have to get a jury award for a lawsuit to be worthwhile. Lots of lawsuits are filed for other reasons by parties aware that a case might never go to trial or that they'll probably never get everything they want.

The possibility of a jury trial actually gives Amarin a good chance in this case because the company has a compelling story that is perfect for a jury, but that's way down the road. With the Teva decision providing wind at its back, Amarin is doing a lot of good with this lawsuit, regardless of the ending.